Testing effectiveness (Phase 2)Study completedNCT01667536
What this trial is testing
Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology
Who this might be right for
Prostate Cancer
Molecular Insight Pharmaceuticals, Inc. 105